US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Inspire Corporate Bond ETF

23.79

+0.02000.08%

Post-market: 23.790.00000.00%18:34 EDT

Volume:54.85K

Turnover:1.30M

Market Cap:383.02M

PE:- -

High:23.89

Open:23.81

Low:23.75

Close:23.77

Loading ...

Overview Company News Filings

Press Release: IonQ Announces Fourth Quarter and Full Year 2024 Financial Results

Biomerica Achieves IVDR Certification in the European Union for Food Intolerance Tests Targeting Crohn’s Disease and Ulcerative Colitis

Organovo’s FXR Program, including FXR314, to Be Acquired by Eli Lilly and Company

Sanofi/Teva Unveil New Detailed Data For Duvakitug Study Supporting Overall Efficacy For Common Inflammatory Bowel Disease

Teva and Sanofi Present New Positive Phase 2b Study Results at ECCO 2025 Reinforcing Best-in-Class Potential of Duvakitug (Anti-TL1A) in Ulcerative Colitis and Crohn’s Disease

TREMFYA® (guselkumab) subcutaneous (SC) induction data support potential to be the first and only in its class to offer the option of both intravenous and SC induction therapy in ulcerative colitis

Howmet Aerospace Lands On Best Stocks List: Check Out Stock Spotlight, IBD 50, Others

S&P 500 Insurance Broker, IBD Stock Of The Day, Gains On Buy Point After 43% Surge

Spyre Therapeutics Announces Poster Presentation at the 20th Congress of the European Crohn's and Colitis Organisation

VYNE Therapeutics Initiates Phase 1b Trial of VYN202, a Novel BD2-Selective Oral BET Inhibitor, in Plaque Psoriasis

Stock Market Shows Positive Reversal, But S&P 500, Nasdaq Trail These Other Indexes; IBD 50 Index Falls

Rambus Rambo's Its Way Onto IBD Top Stocks List: Check Out IBD 50, Sector Leaders, Others

Penguin Solutions Stock Sees IBD RS Rating Rise To 79

IBD Rating Upgrades: Western Digital Shows Improved Price Strength

T-Mobile Hits Record High, Joins Big Cap 20: Check Out New Names On IBD 50, Stock Spotlight And More

Schrodinger Stock Scores IBD Rating Upgrade

Howmet Aerospace, IBD Stock Of The Day, Unfazed By Trump Defense Budget Comments

Three Stocks Hover Near Buy Points In Outstanding Week For IBD 50

Nxera Pharma Operational Highlights and Consolidated Results for the Fourth Quarter and Full Year 2024

AppLovin Getting Lots Of Love From Investors: Check It And Other Top Stocks Out On The IBD 50, Big Cap 20, Other Lists

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Trading app for stocks, options & ETFs","description":"Invest in US, ASX, HK, China A-shares, ETFs & options with Tiger Brokers, Australia's trusted stock trading app!","keywords":"tiger brokers,tiger brokers au,tiger brokers australia,tiger trade,tiger trading,australia stock platform,US option,US stocks,stocks and options,australian trading platform,online broker australia,stock trading apps,mobile trading app,desktop trading,chess sponsored brokers,share trading platform","social":{"ogDescription":"Invest in US, ASX, HK, China A-shares, ETFs & options with Tiger Brokers, Australia's trusted stock trading app!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/IBD/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"AUS","license":"TBAU","edition":"fundamental","symbol":"IBD","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IBD\",,,,,undefined,":{"symbol":"IBD","market":"US","secType":"STK","nameCN":"Inspire Corporate Bond ETF","latestPrice":23.79,"timestamp":1743624000000,"preClose":23.77,"halted":0,"volume":54848,"hourTrading":{"tag":"盘后","latestPrice":23.79,"preClose":23.79,"latestTime":"18:34 EDT","volume":4,"amount":95.16,"timestamp":1743633291706},"delay":0,"floatShares":16100000,"shares":16100000,"eps":0,"marketStatus":"Closed","change":0.02,"latestTime":"04-02 16:00:00 EDT","open":23.81,"high":23.89,"low":23.75,"amount":1304614.5280000002,"amplitude":0.00589,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Market Trading","tradingStatus":1,"beginTime":1743667200000},"marketStatusCode":5,"adr":0,"adrRate":0,"exchange":"ARCA","adjPreClose":23.77,"sharesOutstanding":16100000,"nav":23.77,"aum":382639341.88,"bidAskSpread":0.002765,"preHourTrading":{"tag":"盘前","latestPrice":23.77,"preClose":23.77,"latestTime":"08:47 EDT","volume":7,"amount":166.39,"timestamp":1743598023825},"postHourTrading":{"tag":"盘后","latestPrice":23.79,"preClose":23.79,"latestTime":"18:34 EDT","volume":4,"amount":95.16,"timestamp":1743633291706},"volumeRatio":0.655587},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IBD\",,,,,undefined,":{"symbol":"IBD","floatShares":16100000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.655587,"shares":16100000,"dividePrice":0.9757,"high":23.89,"amplitude":0.00589,"preClose":23.77,"low":23.75,"week52Low":22.84,"pbRate":"--","week52High":25.49,"institutionHeld":0,"latestPrice":23.79,"eps":0,"divideRate":0.041013,"volume":54848,"delay":0,"ttmEps":0,"open":23.81,"prevYearClose":23.44,"prevWeekClose":23.7,"prevMonthClose":23.75,"prevQuarterClose":23.75,"fiveDayClose":23.745,"twentyDayClose":23.71,"sixtyDayClose":23.5},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"IBD\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2514860594","title":"Press Release: IonQ Announces Fourth Quarter and Full Year 2024 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2514860594","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514860594?lang=en_us&edition=fundamental","pubTime":"2025-02-27 05:05","pubTimestamp":1740603900,"startTime":"0","endTime":"0","summary":"Exceeds High End of Guidance Range with Full Year Revenue of $43.1. Exceeds High End of Guidance Range with Full Year Bookings of $95.6. Leading Quantum Networking Provider, to Further IonQ's Global Quantum. IonQ , a leader in the quantum computing and networking industries, today announced financial results for the quarter and full year ended December 31, 2024.\"We had IonQ's best year yet in 2024, exceeding the high ends of both our bookings and revenue guidance ranges and making truly significant technical strides,\" said Peter Chapman, IonQ's Executive Chair.\"As we enter 2025, IonQ has a strong pipeline that we believe will enable us to lead in the era of commercial advantage. Last year, our rapidly expanding quantum networking business line closed three major networking contracts. McKinsey expects the quantum networking industry to be worth $10-15 billion per year within the next decade,\" noted Chapman.IonQ recognized revenue of $11.7 million for the quarter, exceeding the. IonQ rec","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4602","BK4170","BK4591","IONQ","IBD"],"gpt_icon":1},{"id":"2514837063","title":"Biomerica Achieves IVDR Certification in the European Union for Food Intolerance Tests Targeting Crohn’s Disease and Ulcerative Colitis","url":"https://stock-news.laohu8.com/highlight/detail?id=2514837063","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514837063?lang=en_us&edition=fundamental","pubTime":"2025-02-26 21:19","pubTimestamp":1740575940,"startTime":"0","endTime":"0","summary":"Significant Milestone: Biomerica secures IVDR (In Vitro Diagnostic Regulation) certification, ensuring compliance with stringent European Union standards and allowing sales of the products in the EUFo","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/02/26/3032903/0/en/Biomerica-Achieves-IVDR-Certification-in-the-European-Union-for-Food-Intolerance-Tests-Targeting-Crohn-s-Disease-and-Ulcerative-Colitis.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BMRA","BK4082","IBD"],"gpt_icon":0},{"id":"2514099424","title":"Organovo’s FXR Program, including FXR314, to Be Acquired by Eli Lilly and Company","url":"https://stock-news.laohu8.com/highlight/detail?id=2514099424","media":"GlobeNewswire","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514099424?lang=en_us&edition=fundamental","pubTime":"2025-02-25 21:05","pubTimestamp":1740488700,"startTime":"0","endTime":"0","summary":"SAN DIEGO, Feb.  25, 2025  (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq:ONVO) (“Organovo” or the “Company”), a clinical stage biotechnology company focused on developing novel treatment approac","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"3ae64dabd38a125634a5edcda736adba","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/02/25/3032003/37000/en/Organovo-s-FXR-Program-including-FXR314-to-Be-Acquired-by-Eli-Lilly-and-Company.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1057294990.SGD","BK4534","LU0256863902.USD","IE00B4R5TH58.HKD","SG9999015978.USD","IE0004445239.USD","LU2461242641.AUD","LU2491050154.USD","BK4599","LU0417517546.SGD","BK4588","GB00BDT5M118.USD","LU0203201768.USD","BK4585","ONVO","SG9999014898.SGD","SGXZ57979304.SGD","LU2112291526.USD","IBD","SG9999018865.SGD","LU2106854487.HKD","LU2361044949.HKD","IE0002141913.USD","LU1712237335.SGD","LU1023059063.AUD","LU1983299246.USD","LU2491050071.SGD","SG9999013999.USD","LU1267930730.SGD","LU0106261372.USD","LU0820561818.USD","IE00B2B36J28.USD","LU0058720904.USD","SGXZ31699556.SGD","LU1868836757.USD","LLY","SGXZ81514606.USD","IE00BJLML261.HKD","LU1291159041.SGD","FXR","LU1093756325.SGD","LU1868837136.USD","SGXZ99366536.SGD","LU0289739699.SGD","LU2063271972.USD","LU0114720955.EUR","LU0471298694.HKD","LU2357305700.SGD","LU2360106947.USD","IE00BFTCPJ56.SGD"],"gpt_icon":1},{"id":"2513721338","title":"Sanofi/Teva Unveil New Detailed Data For Duvakitug Study Supporting Overall Efficacy For Common Inflammatory Bowel Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2513721338","media":"Benzinga","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513721338?lang=en_us&edition=fundamental","pubTime":"2025-02-24 21:22","pubTimestamp":1740403320,"startTime":"0","endTime":"0","summary":"On Saturday, Teva Pharmaceuticals Industries Ltd.  and Sanofi SA  presented new, detailed results from the RELIEVE UCCD Phase 2b study of duvakitug  for moderate-to-severe ulcerative colitis  and Crohn’s disease , the two most common forms of inflammatory bowel disease .These results were shared at the Congress of the European Crohn’s and Colitis Organisation.Also Read: Axsome Therapeutics Resolves Generic Patent Litigation With Teva Over Depression Drug, Analyst Maintains Axsome As ‘Top Pick For 2025’。In the UC cohort of the RELIEVE UCCD study, 36%  and 48%  of patients treated with duvakitug achieved the primary endpoint of clinical remission  at week 14 compared to 20% treated with placebo.Higher clinical remission rates were observed for both doses of duvakitug versus placebo in both advanced therapy -experienced and AT-nave subgroups of patients.AT-experienced: 29%  and 36% , with placebo-adjusted rates of 22%  and 29% .AT-nave: 39%  and 53% , with placebo-adjusted rates of 12%  a","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/sanofi-teva-unveil-detailed-data-132200188.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4584","BK4559","SNY","BK4566","BK4585","BK4588","BK4557","BK4596","CD","BK4116","IE00BFXG1179.USD","SNYNF","TEVA","BK4007","IBD"],"gpt_icon":0},{"id":"2513141222","title":"Teva and Sanofi Present New Positive Phase 2b Study Results at ECCO 2025 Reinforcing Best-in-Class Potential of Duvakitug (Anti-TL1A) in Ulcerative Colitis and Crohn’s Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2513141222","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513141222?lang=en_us&edition=fundamental","pubTime":"2025-02-22 15:20","pubTimestamp":1740208800,"startTime":"0","endTime":"0","summary":"Teva hosting investor call Monday, February 24 at 8:00 a.m. U.S. ETNew detailed data from the RELIEVE UCCD study support overall efficacy and safety of duvakitug in all pre-specified subgroups across ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/02/22/3030763/0/en/Teva-and-Sanofi-Present-New-Positive-Phase-2b-Study-Results-at-ECCO-2025-Reinforcing-Best-in-Class-Potential-of-Duvakitug-Anti-TL1A-in-Ulcerative-Colitis-and-Crohn-s-Disease.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4585","BK4116","BK4588","IE00BFXG1179.USD","SNY","CD","SNYNF","IBD"],"gpt_icon":0},{"id":"2513641582","title":"TREMFYA® (guselkumab) subcutaneous (SC) induction data support potential to be the first and only in its class to offer the option of both intravenous and SC induction therapy in ulcerative colitis","url":"https://stock-news.laohu8.com/highlight/detail?id=2513641582","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513641582?lang=en_us&edition=fundamental","pubTime":"2025-02-21 20:00","pubTimestamp":1740139200,"startTime":"0","endTime":"0","summary":"Phase 3 ASTRO study achieves primary and all secondary endpoints at Week 12 in ulcerative colitis patients. The only SC induction data for an IL-23 inhibitor show statistically significant and clinically meaningful improvements across clinical and endoscopic measures versus placebo, consistent with IV induction. SPRING HOUSE, Pa., Feb. 21, 2025 /PRNewswire/ --Johnson & Johnson today announced data from the Phase 3 ASTRO study of TREMFYA  subcutaneous  induction therapy in adults with moderately to severely active ulcerative colitis  at the 20thCongress of the European Crohn's and Colitis Organization .Study findings through Week 12 showed statistically significant and clinically meaningful improvements compared to placebo across all clinical and endoscopic measures consistent with the U.S. Food and Drug Administration -approved intravenous  induction regimen in this population.1","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/tremfya-guselkumab-subcutaneous-sc-induction-120000814.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/tremfya-guselkumab-subcutaneous-sc-induction-120000814.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU1732799900.SGD","LU2430703178.SGD","LU2592432038.USD","IE00B42XCP33.USD","LU1894683264.USD","IE0009355771.USD","LU1074936037.SGD","BK4116","LU1221951046.USD","LU2129689514.USD","LU1267930813.SGD","LU0345770993.USD","LU2602419157.SGD","LU2505996509.AUD","LU1244550577.SGD","LU1221951129.SGD","LU2430703251.USD","LU0345770308.USD","LU0122379950.USD","LU1066053197.SGD","LU0234572021.USD","LU1066051225.USD","LU0345769128.USD","LU1196500208.SGD","BK4588","JNJ","BK4504","LU0795875169.SGD","LU0792757196.USD","LU1032955483.USD","LU1162221912.USD","LU1430594728.SGD","LU1506573853.SGD","CD","LU0466842654.USD","LU1674673428.USD","LU1935042991.SGD","LU0889566641.SGD","SG9999001440.SGD","LU1894683348.USD","LU1674673691.USD","IE00B19Z3581.USD","IBD","IE00B3PB1722.GBP","LU2468319806.SGD","LU0320765646.SGD","LU0912757837.SGD","BK4592","IE00B7SZLL34.SGD","LU0058720904.USD"],"gpt_icon":0},{"id":"2512454955","title":"Howmet Aerospace Lands On Best Stocks List: Check Out Stock Spotlight, IBD 50, Others","url":"https://stock-news.laohu8.com/highlight/detail?id=2512454955","media":"Blockhead","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512454955?lang=en_us&edition=fundamental","pubTime":"2025-02-20 08:06","pubTimestamp":1740009976,"startTime":"0","endTime":"0","summary":"IBD’s top-performing stock lists have just been updated. See which stocks like Howmet Aerospace got added – and which got cut.","market":"hk","thumbnail":"https://www.investors.com/wp-content/uploads/2018/03/ibdstocksupdate1-150x150.jpg","type":0,"news_type":0,"thumbnails":["https://www.investors.com/wp-content/uploads/2018/03/ibdstocksupdate1-150x150.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.investors.com/news/howmet-aerospace-lands-on-best-stocks-list-check-out-stock-spotlight-ibd-50-others/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"investor_business_daily_highlight","symbols":["BK4187","IBD","LU1153585028.USD","BK4196","LU0061474960.USD","LU0957791311.USD","LU0096362180.USD","BK4588","BK4585","LU0011850046.USD","HIMS","HWM","LU1815333072.USD"],"gpt_icon":0},{"id":"2512386964","title":"S&P 500 Insurance Broker, IBD Stock Of The Day, Gains On Buy Point After 43% Surge","url":"https://stock-news.laohu8.com/highlight/detail?id=2512386964","media":"Blockhead","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512386964?lang=en_us&edition=fundamental","pubTime":"2025-02-20 01:16","pubTimestamp":1739985405,"startTime":"0","endTime":"0","summary":"Brown & Brown stock has started 2025 by gaining more than 8%.","market":"us","thumbnail":"https://www.investors.com/wp-content/uploads/2025/02/sotd-for-02-19-2025-desktop-150x150.png","type":0,"news_type":0,"thumbnails":["https://www.investors.com/wp-content/uploads/2025/02/sotd-for-02-19-2025-desktop-150x150.png"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.investors.com/research/ibd-stock-of-the-day/sp-500-brownbrown-stock-insurance-surged-last-year-gaining-on-buy-point/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"investor_business_daily_highlight","symbols":["SPXU","ESmain","SPY","BK4559","SSO","BK4585","UPRO","SH","IVV","VOO","BK4504","OEX","SDS","BK4597","BRO","IBD","OEF","BK4173","BK4581","BK4534",".SPX","BK4588","BK4550","IE00BKPKM429.USD","LU2108987350.USD"],"gpt_icon":0},{"id":"2512877102","title":"Spyre Therapeutics Announces Poster Presentation at the 20th Congress of the European Crohn's and Colitis Organisation","url":"https://stock-news.laohu8.com/highlight/detail?id=2512877102","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512877102?lang=en_us&edition=fundamental","pubTime":"2025-02-19 21:00","pubTimestamp":1739970000,"startTime":"0","endTime":"0","summary":"WALTHAM, Mass., Feb. 19, 2025 /PRNewswire/ -- Spyre Therapeutics, Inc.  , a clinical-stage biotechnology company advancing best-in-class antibody engineering, dose optimization, and rational therapeutic combinations for the treatment of Inflammatory Bowel Disease  and other immune-mediated diseases, today announced a poster presentation at the 20th Congress of the European Crohn's and Colitis Organisation , held February 19-22, 2025, in Berlin, Germany, showing that combined inhibition of α4β7 integrin and TL1A cytokine is superior to either monotherapy in mouse models of colitis and coadministration demonstrates no drug-drug effects on exposure in non-human primates .Forward-Looking StatementsCertain statements in this press release, other than purely historical information, may constitute \"forward-looking statements\" within the meaning of the federal securities laws, including for purpos","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/spyre-therapeutics-announces-poster-presentation-130000431.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/spyre-therapeutics-announces-poster-presentation-130000431.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["SYRE","LENZ","IBD","BK4139"],"gpt_icon":0},{"id":"2512839104","title":"VYNE Therapeutics Initiates Phase 1b Trial of VYN202, a Novel BD2-Selective Oral BET Inhibitor, in Plaque Psoriasis","url":"https://stock-news.laohu8.com/highlight/detail?id=2512839104","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512839104?lang=en_us&edition=fundamental","pubTime":"2025-02-19 21:00","pubTimestamp":1739970000,"startTime":"0","endTime":"0","summary":"Oral, once-daily doses of VYN202 being evaluated in subjects with moderate-to-severe plaque psoriasis Top-line data from the 12-week double-blind trial expected by year-end 2025 Phase 1b trial designe","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/02/19/3028700/0/en/VYNE-Therapeutics-Initiates-Phase-1b-Trial-of-VYN202-a-Novel-BD2-Selective-Oral-BET-Inhibitor-in-Plaque-Psoriasis.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","IBD","VYNE"],"gpt_icon":0},{"id":"2512612814","title":"Stock Market Shows Positive Reversal, But S&P 500, Nasdaq Trail These Other Indexes; IBD 50 Index Falls","url":"https://stock-news.laohu8.com/highlight/detail?id=2512612814","media":"Blockhead","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512612814?lang=en_us&edition=fundamental","pubTime":"2025-02-19 09:45","pubTimestamp":1739929525,"startTime":"0","endTime":"0","summary":"Both Reddit and Shift4 are members of the IBD 50.","market":"us","thumbnail":"https://www.investors.com/wp-content/uploads/2020/05/Stock-Bull-fighting-06-adobe-150x150.jpg","type":0,"news_type":0,"thumbnails":["https://www.investors.com/wp-content/uploads/2020/05/Stock-Bull-fighting-06-adobe-150x150.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.investors.com/market-trend/the-big-picture/stock-market-shows-positive-reversal-but-s-ibd-50-index-falls/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"investor_business_daily_highlight","symbols":["BK4559","BK4112","NDAQ","SH","SPY","IE00B64PRP62.GBP","IE00B3QW5Z07.USD","IBD","IE00BGHQF748.EUR","USJW.SI","IE00BKPKM429.USD","QQQ","TSYW.SI","LU2095319765.USD","BK4534",".IXIC","IVV","NVIW.SI","LU2210149790.SGD","TQQQ","QLD","BK4588","BK4585","OEF","BK4504","BK4550","MNQmain","SSO","QID","USAW.SI","NQmain","PSQ","SPXU","UPRO","LU2210150020.SGD","VOO","BK4581","SQQQ","ESmain",".SPX","OEX","SDS"],"gpt_icon":0},{"id":"2512117459","title":"Rambus Rambo's Its Way Onto IBD Top Stocks List: Check Out IBD 50, Sector Leaders, Others","url":"https://stock-news.laohu8.com/highlight/detail?id=2512117459","media":"Blockhead","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512117459?lang=en_us&edition=fundamental","pubTime":"2025-02-19 07:57","pubTimestamp":1739923038,"startTime":"0","endTime":"0","summary":"IBD’s top-performing stock lists have just been updated. See which stocks like Rambus got added – and which got cut.","market":"sg","thumbnail":"https://www.investors.com/wp-content/uploads/2018/03/ibdstocksupdate3-150x150.jpg","type":0,"news_type":0,"thumbnails":["https://www.investors.com/wp-content/uploads/2018/03/ibdstocksupdate3-150x150.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.investors.com/research/rambus-rambos-its-way-onto-ibd-top-stocks-list-check-out-ibd-50-sector-leaders-others/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"investor_business_daily_highlight","symbols":["BK4106","BK4141","BK4227","PAY","BK4539","BK4585","RMBS","IBD"],"gpt_icon":0},{"id":"2512197424","title":"Penguin Solutions Stock Sees IBD RS Rating Rise To 79","url":"https://stock-news.laohu8.com/highlight/detail?id=2512197424","media":"Blockhead","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512197424?lang=en_us&edition=fundamental","pubTime":"2025-02-19 05:05","pubTimestamp":1739912700,"startTime":"0","endTime":"0","summary":"A Relative Strength Rating upgrade for Penguin Solutions shows improving technical performance. Will it continue?","market":"us","thumbnail":"https://www.investors.com/wp-content/uploads/2017/05/IRU4-150x150.jpg","type":0,"news_type":0,"thumbnails":["https://www.investors.com/wp-content/uploads/2017/05/IRU4-150x150.jpg"],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.investors.com/news/technology/penguin-solutions-stock-sees-ibd-rs-rating-rise-to-79/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"investor_business_daily_highlight","symbols":["IBD","RS"],"gpt_icon":0},{"id":"2512191426","title":"IBD Rating Upgrades: Western Digital Shows Improved Price Strength","url":"https://stock-news.laohu8.com/highlight/detail?id=2512191426","media":"Blockhead","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512191426?lang=en_us&edition=fundamental","pubTime":"2025-02-18 16:00","pubTimestamp":1739865600,"startTime":"0","endTime":"0","summary":"Western Digital shows rising price performance, earning an upgrade to its IBD Relative Strength Rating","market":"us","thumbnail":"https://www.investors.com/wp-content/uploads/2017/05/IRU2-150x150.jpg","type":0,"news_type":0,"thumbnails":["https://www.investors.com/wp-content/uploads/2017/05/IRU2-150x150.jpg"],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.investors.com/ibd-data-stories/ibd-rating-upgrades-western-digital-shows-improved-price-strength/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"investor_business_daily_highlight","symbols":["IBD","WDC"],"gpt_icon":0},{"id":"2511564724","title":"T-Mobile Hits Record High, Joins Big Cap 20: Check Out New Names On IBD 50, Stock Spotlight And More","url":"https://stock-news.laohu8.com/highlight/detail?id=2511564724","media":"Blockhead","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2511564724?lang=en_us&edition=fundamental","pubTime":"2025-02-15 07:51","pubTimestamp":1739577073,"startTime":"0","endTime":"0","summary":"See which stocks like T-Mobile US have just been added to – or in some cases removed from – IBD’s stock lists, including the IBD 50, Sector Leaders, IBD Big Cap 20 and IPO Leaders.","market":"sg","thumbnail":"https://www.investors.com/wp-content/uploads/2018/03/ibdstocksupdate2-150x150.jpg","type":0,"news_type":0,"thumbnails":["https://www.investors.com/wp-content/uploads/2018/03/ibdstocksupdate2-150x150.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.investors.com/research/check-out-new-names-on-ibd-50-stock-spotlight-more/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"investor_business_daily_highlight","symbols":["FOXA","BK4116","SHOP","BK4566","LU1861559042.SGD","TEM.AU","BK4551","LU2265009873.SGD","BK4125","LU0823421416.USD","IBD","BK4528","LU1861558580.USD","LU0823421333.USD","LU1720051108.HKD","LU1720051017.SGD","BK4524","TEM","LU0390134368.USD","BK4121","LU2357305700.SGD","BK4588","BK7095","LU1804176565.USD","BK4585","BK4532","LU1548497426.USD","BK4548"],"gpt_icon":0},{"id":"2511103936","title":"Schrodinger Stock Scores IBD Rating Upgrade","url":"https://stock-news.laohu8.com/highlight/detail?id=2511103936","media":"Blockhead","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2511103936?lang=en_us&edition=fundamental","pubTime":"2025-02-15 04:47","pubTimestamp":1739566020,"startTime":"0","endTime":"0","summary":"Schrodinger shows improving price performance, earning an upgrade to its IBD Relative Strength Rating","market":"hk","thumbnail":"https://www.investors.com/wp-content/uploads/2017/05/IRU2-150x150.jpg","type":0,"news_type":0,"thumbnails":["https://www.investors.com/wp-content/uploads/2017/05/IRU2-150x150.jpg"],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.investors.com/news/schrodinger-stock-scores-ibd-rating-upgrade/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"investor_business_daily_highlight","symbols":["SDGR","IBD"],"gpt_icon":0},{"id":"2511619846","title":"Howmet Aerospace, IBD Stock Of The Day, Unfazed By Trump Defense Budget Comments","url":"https://stock-news.laohu8.com/highlight/detail?id=2511619846","media":"Blockhead","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2511619846?lang=en_us&edition=fundamental","pubTime":"2025-02-15 02:30","pubTimestamp":1739557858,"startTime":"0","endTime":"0","summary":"Howmet Aerospace breaks out to record highs after earnings. Defense stocks pull back after Trump proposes 50% budget cut.","market":"hk","thumbnail":"https://www.investors.com/wp-content/uploads/2025/02/sotd-for-02-14-2025-desktop-150x150.png","type":0,"news_type":0,"thumbnails":["https://www.investors.com/wp-content/uploads/2025/02/sotd-for-02-14-2025-desktop-150x150.png"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.investors.com/research/ibd-stock-of-the-day/howmet-aerospace-hwm-stock-buy-point-earnings-trump-defense-budget/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"investor_business_daily_highlight","symbols":["IBD"],"gpt_icon":0},{"id":"2511613169","title":"Three Stocks Hover Near Buy Points In Outstanding Week For IBD 50","url":"https://stock-news.laohu8.com/highlight/detail?id=2511613169","media":"Blockhead","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2511613169?lang=en_us&edition=fundamental","pubTime":"2025-02-15 01:51","pubTimestamp":1739555504,"startTime":"0","endTime":"0","summary":"The Innovator IBD 50 ETF is headed for a week of outstanding gains. Three stocks in the ETF are near buy points.","market":"nz","thumbnail":"https://www.investors.com/wp-content/uploads/2018/10/Stock-AxonVest-04-company-150x150.jpg","type":0,"news_type":0,"thumbnails":["https://www.investors.com/wp-content/uploads/2018/10/Stock-AxonVest-04-company-150x150.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.investors.com/stock-lists/ibd-50/stock-market-ibd-50-axon-samsara-iot-stock/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"investor_business_daily_highlight","symbols":["BK4585","BK4588","BK4550","BK4122","PCOM","FDN","IBD","FFTY"],"gpt_icon":0},{"id":"2511634146","title":"Nxera Pharma Operational Highlights and Consolidated Results for the Fourth Quarter and Full Year 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2511634146","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2511634146?lang=en_us&edition=fundamental","pubTime":"2025-02-14 14:30","pubTimestamp":1739514600,"startTime":"0","endTime":"0","summary":"Tokyo, Japan and Cambridge, UK, 14 February 2025 – Nxera Pharma Co., Ltd.  provides an update on operational activities and reports its consolidated results for the fourth quarter and 12 months ended 31 December 2024. The full report can be viewed here.Chris Cargill, President & CEO of Nxera, commented: “2024 was a transformational year for Nxera during which we made excellent progress under our new company name and brand towards becoming a leading technology driven biopharmaceutical company bringing new medicines to patients in Japan and globally.“We made fantastic commercial progress, with two products – PIVLAZ and QUVIVIQ  – recently launched in Japan driving top line revenue growth. We plan to make these products available to patients in South Korea shortly, in addition to other key APAC markets .Q4 2024 net sales of JPY 4,282 million, FY 2024 net sales of JPY 12,651 million (US$83.5 million, repr","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/nxera-pharma-operational-highlights-consolidated-063000928.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4233","BK4528","BK4205","CNSL","BK4115","BK4007","UK","SOLTF","IBD"],"gpt_icon":0},{"id":"2511688229","title":"AppLovin Getting Lots Of Love From Investors: Check It And Other Top Stocks Out On The IBD 50, Big Cap 20, Other Lists","url":"https://stock-news.laohu8.com/highlight/detail?id=2511688229","media":"Blockhead","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2511688229?lang=en_us&edition=fundamental","pubTime":"2025-02-14 07:55","pubTimestamp":1739490951,"startTime":"0","endTime":"0","summary":"Here’s a list of all the top-rated growth stocks that have just been added to the IBD 50, IBD Big Cap 20, Sector Leaders, Stock Spotlight and IPO leaders.","market":"fut","thumbnail":"https://www.investors.com/wp-content/uploads/2018/03/ibdstocksupdate4-150x150.jpg","type":0,"news_type":0,"thumbnails":["https://www.investors.com/wp-content/uploads/2018/03/ibdstocksupdate4-150x150.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.investors.com/research/check-out-top-stocks-on-the-ibd-50-big-cap-20-others/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"investor_business_daily_highlight","symbols":["IBD","BK4211","BK4539","BK4023","BK4608","BK4585","BK4588","APP","ISBC"],"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":2,"totalSize":200}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/IBD\",params:#limit:5,,,undefined,":[{"date":"2025-03-27","symbol":"IBD","amount":0.092,"announcedDate":"2025-03-26","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-03-27","defaultRemindTime":1743082200000,"name":"Inspire Corporate Bond ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-04-01","payableDate":"2025-03-27","currency":"USD","dateTimestamp":1743048000000,"payDate":"2025-04-01"},{"date":"2025-02-24","symbol":"IBD","amount":0.0728,"announcedDate":"2025-02-21","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-02-24","defaultRemindTime":1740407400000,"name":"Inspire Corporate Bond ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-03-03","payableDate":"2025-02-24","currency":"USD","dateTimestamp":1740373200000,"payDate":"2025-03-03"},{"date":"2025-01-27","symbol":"IBD","amount":0.0599,"announcedDate":"2025-01-24","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-01-27","defaultRemindTime":1737988200000,"name":"Inspire Corporate Bond ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-02-03","payableDate":"2025-01-27","currency":"USD","dateTimestamp":1737954000000,"payDate":"2025-02-03"},{"date":"2024-12-16","symbol":"IBD","amount":0.1181,"announcedDate":"2024-12-13","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-12-16","defaultRemindTime":1734359400000,"name":"Inspire Corporate Bond ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-12-23","payableDate":"2024-12-16","currency":"USD","dateTimestamp":1734325200000,"payDate":"2024-12-23"},{"date":"2024-11-22","symbol":"IBD","amount":0.0748,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-11-22","defaultRemindTime":1732285800000,"name":"Inspire Corporate Bond ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-11-29","payableDate":"2024-11-22","currency":"USD","dateTimestamp":1732251600000,"payDate":"2024-11-29"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"IBD\",market:\"US\",,,undefined,":[{"executeDate":"2017-08-16","recordDate":"2017-08-18","paymentDate":"2017-08-23","value":0.0405,"currency":"USD"},{"executeDate":"2017-09-18","recordDate":"2017-09-19","paymentDate":"2017-09-25","value":0.0292,"currency":"USD"},{"executeDate":"2017-10-16","recordDate":"2017-10-17","paymentDate":"2017-10-23","value":0.0347,"currency":"USD"},{"executeDate":"2017-11-16","recordDate":"2017-11-17","paymentDate":"2017-11-28","value":0.0389,"currency":"USD"},{"executeDate":"2018-01-29","recordDate":"2018-01-30","paymentDate":"2018-02-05","value":0.0269,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"IBD\",market:\"US\",delay:false,,,undefined,":{}}}